SBBP Strongbridge Biopharma plc

2.8
-0.06  -2%
Previous Close 2.86
Open 2.82
Price To Book 1.56
Market Cap 151,681,771
Shares 54,172,061
Volume 10,476
Short Ratio
Av. Daily Volume 267,655

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data expected 1Q 2020.
COR-003 (levoketoconazole) - LOGICS
Endogenous Cushing’s syndrome
NDA to be filed 3Q 2020.
COR-003 (levoketoconazole) - SONICS
Endogenous Cushing’s syndrome

Latest News

  1. Is Strongbridge Biopharma plc's (NASDAQ:SBBP) ROE Of 43% Impressive?
  2. Strongbridge Biopharma plc Added to the Russell 3000® and Microcap® Indexes
  3. Here’s What Hedge Funds Think About Strongbridge Biopharma plc (SBBP)
  4. Strongbridge Biopharma plc Strengthens Senior Leadership Team with Key Promotion and Appointment
  5. Strongbridge Biopharma plc to Present at the Jefferies 2019 Global Healthcare Conference
  6. Strongbridge Biopharma plc Presents KEVEYIS® (dichlorphenamide) Primary Periodic Paralysis (PPP) Data at the 2019 American Academy of Neurology Annual Meeting
  7. Edited Transcript of SBBP earnings conference call or presentation 1-May-19 12:30pm GMT
  8. Edited Transcript of SBBP earnings conference call or presentation 26-Feb-19 1:30pm GMT
  9. Strongbridge Biopharma (SBBP) Q1 2019 Earnings Call Transcript
  10. Strongbridge Biopharma (SBBP) Reports Q1 Loss, Lags Revenue Estimates
  11. Strongbridge Biopharma plc (SBBP) Q1 2019 Earnings Call Transcript
  12. Strongbridge Biopharma plc Reports First Quarter 2019 Financial Results and Provides Corporate Update
  13. News Surrounds 3 Small Biotechs, With a Merger Claiming One
  14. The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug
  15. Strongbridge Biopharma plc Announces Presentation of New Secondary Endpoint Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 American Association of Clinical Endocrinologists Annual Scientific and Clinical Congress
  16. Strongbridge Biopharma plc to Host First Quarter 2019 Financial Results Conference Call on May 1, 2019
  17. Does Strongbridge Biopharma plc's (NASDAQ:SBBP) CEO Pay Compare Well With Peers?
  18. Strongbridge Biopharma plc Announces Upcoming Presentation of New Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 American Association of Clinical Endocrinologists (AACE) Annual Scientific and Clinical Congress
  19. Strongbridge Biopharma plc Announces Presentation of New Data Analyses from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Potential Treatment of Endogenous Cushing’s Syndrome
  20. Is Strongbridge Biopharma plc (NASDAQ:SBBP) Potentially Underrated?